Deciphering the Risk of Developing Second Primary Thyroid Cancer Following a Primary Malignancy-Who Is at the Greatest Risk?

BACKGROUND

It is critical to understand factors that may contribute to an increased risk of SPTC in order to develop surveillance protocols in high-risk individuals. This systematic review and meta-analysis will assess the association between primary malignancy and SPTC.

METHODS

A search of PubMed and Embase databases was completed in April 2020. Inclusion criteria included studies that reported the incidence or standardized incidence ratio of any primary malignancy and SPTC, published between 1980-2020. The PRISMA guidelines were followed and the Newcastle-Ottawa Scale was used to assess quality of studies.

RESULTS

40 studies were included, which were comprised of 1,613,945 patients and 15 distinct types of primary cancers. In addition, 4196 (0.26%) patients developed SPTC following a mean duration of 8.07 ± 4.39 years. Greater risk of developing SPTC was found following primary breast (56.6%, 95%CI, 44.3-68.9, < 0.001), renal cell (12.2%, 95%CI, 7.68-16.8, < 0.001), basal cell (7.79%, 95%CI, 1.79-13.7, = 0.011), and ovarian cancer (11.4%, 95%CI, 3.4-19.5, = 0.005). SPTC patients were more likely to be females (RR = 1.58, 95%CI, 1.2-2.01, < 0.001) and Caucasians ( < 0.001).

CONCLUSIONS

Surveillance protocols should be considered for patients at a higher risk of SPTC, including those with primary breast, renal cell, basal cell and ovarian cancers who are female and/or Caucasian.